USSTOCK.TODAY
Pre-Market
Log in Sign up

Genmab reports 22% increase in total revenue for first nine months of 2026

The Motley Fool +1 · ·by G4L

GMAB Genmab ADR
$55.80 +4.05%
View chart & analysis →
  1. 1Genmab recorded a 22% increase in total revenue for the first nine months of 2026.
  2. 2EPKINLY revenue grew by 47% during the first nine months, reaching $491 million.
  3. 3CFO Anthony Pagano maintained the 2026 financial guidance.

So what's the key point?

Genmab's revenue grew by 22 percent. As EPKINLY sales increased, the company is able to maintain the goals it set for this year.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Zenmap confirms 50% reduction in death risk in first-line head and neck squamous cell carcinoma clinical trial Clinical Trials Arena · Oct 30Genmab shares surge 13% following announcement of colorectal cancer treatment clinical results Investing.com · Oct 26Genmab shares rise 9% on positive Phase 3 clinical trial results for ovarian cancer treatment Investing.com +1 · Oct 24
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news